Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 2/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2897176 | 1.00 | CHRM5 (0.41) | CHRM5CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL13025301 | 1.00 | CHRM5 (0.41) | CHRM5CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL13779618 | 0.82 | CHRM5 (0.39) | CHRM5CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL16885287 | 0.82 | CHRM5 (0.36) | CHRM5CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL13064060 | 0.79 | CHRM5 (0.35) | CHRM5CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL2034622 | 0.79 | CHRM5 (0.40) | CHRM5CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL338034 | 0.78 | MAPT (0.36) | CYP1A2MAPTSMN1; SMN2 | |
| SCHEMBL16889979 | 0.77 | CHRM5 (0.38) | CHRM5CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL9815240 | 0.76 | CYP1A2 (0.47) | CHRM5CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL8226932 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105481801-B | Preparation method of pregabalin chiral intermediate | 广东莱佛士制药技术有限公司 | 2021-08-13 | — | — | CN | claimed |
| US-9925204-B2 | Anti-inflammatory compounds in combination with hydrogen for the treatment of inflammation | KAWAI TOSHIHISA (US) | 2018-03-27 | — | — | US | disclosed |
| US-9925204-B2 | Anti-inflammatory compounds in combination with hydrogen for the treatment of inflammation | KAWAI TOSHIHISA (US) | 2018-03-27 | — | — | US | disclosed |
| US-9545415-B2 | Anti-inflammatory compounds in combination with hydrogen for the treatment of inflammation | SKYVIEW ENTPR LTD (US) | 2017-01-17 | — | — | US | disclosed |
| US-9545415-B2 | Anti-inflammatory compounds in combination with hydrogen for the treatment of inflammation | SKYVIEW ENTPR LTD (US) | 2017-01-17 | — | — | US | disclosed |
| US-20160317575-A1 | ANTI-INFLAMMATORY COMPOUNDS IN COMBINATION WITH HYDROGEN FOR THE TREATMENT OF INFLAMMATION | KAWAI TOSHIHISA (US) | 2016-11-03 | — | — | US | disclosed |
| US-20160317575-A1 | ANTI-INFLAMMATORY COMPOUNDS IN COMBINATION WITH HYDROGEN FOR THE TREATMENT OF INFLAMMATION | KAWAI TOSHIHISA (US) | 2016-11-03 | — | — | US | disclosed |
| CN-105481801-A | Preparation method of pregabalin chiral intermediate | RAFFLES PHARMATECH CO LTD | 2016-04-13 | — | — | CN | disclosed |
| US-9242984-B2 | Pyrazolyl derivatives as Syk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-01-26 | — | — | US | disclosed |
| US-20150191461-A1 | PYRAZOLYL DERIVATIVES AS SYK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-07-09 | — | — | US | disclosed |
| US-20150140090-A1 | ANTI-INFLAMMATORY COMPOUNDS IN COMBINATION WITH HYDROGEN FOR THE TREATMENT OF INFLAMMATION | SKYVIEW ENTPR LTD (US) | 2015-05-21 | — | — | US | disclosed |
| US-20150140090-A1 | ANTI-INFLAMMATORY COMPOUNDS IN COMBINATION WITH HYDROGEN FOR THE TREATMENT OF INFLAMMATION | SKYVIEW ENTPR LTD (US) | 2015-05-21 | — | — | US | disclosed |
| US-20100286442-A1 | NOVEL METHOD FOR PREPARING PREGABALIN | KAIST (KR) | 2010-11-11 | — | — | US | disclosed |
| US-20100286442-A1 | NOVEL METHOD FOR PREPARING PREGABALIN | KAIST (KR) | 2010-11-11 | — | — | US | disclosed |
| US-20100286442-A1 | NOVEL METHOD FOR PREPARING PREGABALIN | KAIST (KR) | 2010-11-11 | — | — | US | disclosed |
| EP-2188244-A2 | NOVEL METHOD FOR PREPARING PREGABALIN | Kaist (KR) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009022839-A2 | NOVEL METHOD FOR PREPARING PREGABALIN | KAIST (KR) | 2009-02-19 | — | — | WO | disclosed |
| WO-2009022839-A2 | NOVEL METHOD FOR PREPARING PREGABALIN | KAIST (KR) | 2009-02-19 | — | — | WO | disclosed |
| US-20080207755-A1 | Alpha 2 Delta Ligands For Fibromyalgia and Other Disorders | PFIZER INC | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191461-A1 | PYRAZOLYL DERIVATIVES AS SYK INHIBITORS | SYK, BTK, LCK | CHRM5 1651/4885CHRM2 1695/4885CHRM4 1836/4885 |
| US-20080207755-A1 | Alpha 2 Delta Ligands For Fibromyalgia and Other Disorders | OPRD1, OPRL1, FFAR3 | CHRM5 204/4885CHRM2 225/4885CHRM4 756/4885 |
| US-20160317575-A1 | ANTI-INFLAMMATORY COMPOUNDS IN COMBINATION WITH HYDROGEN FOR THE TREATMENT OF INFLAMMATION | PTGS1, HVCN1, HRH2 | CHRM5 3316/4885CHRM2 2611/4885CHRM4 2187/4885 |
| US-20100286442-A1 | NOVEL METHOD FOR PREPARING PREGABALIN | GABRA5, GABRE, GABRP | CHRM5 831/4885CHRM2 2437/4885CHRM4 1969/4885 |
| US-20150140090-A1 | ANTI-INFLAMMATORY COMPOUNDS IN COMBINATION WITH HYDROGEN FOR THE TREATMENT OF INFLAMMATION | PTGS1, HVCN1, HRH2 | CHRM5 3316/4885CHRM2 2611/4885CHRM4 2187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.